Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-196b antagomir + lactoferrin-lipid nano-assemblies
- Development stage
- Preclinical
- Lead developer
- Northeastern University
- Modality
- Small Molecules, RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
miR-196b antagomir + lactoferrin-lipid nano-assemblies is an experimental therapeutic designed to treat renal cell carcinoma (RCC) by targeting and remodeling cancer-associated fibroblasts (CAFs). The formulation consists of ultrasmall (5-7 nm) lipid nano-assemblies stabilized by recombinant human lactoferrin (rhLF). These assemblies are co-loaded with an antagomir against the oncomiR miR-196b and a small molecule inhibitor of COUP-TFII (CIA-1). The lactoferrin component serves as a targeting ligand for LRP1 and intelectin-1 receptors, which are overexpressed in fibrotic tumor tissues. By inhibiting miR-196b and COUP-TFII, the drug aims to reprogram immunosuppressive CAFs into a quiescent phenotype, thereby reducing the secretion of pro-inflammatory cytokines (IL-6, IL-8, MCP1) and enhancing the efficacy of cancer immunotherapy.
- Other names
- rhLF-lipid NAs co-loaded with antagomir (anti-miR 196b) and COUP-TFII inhibitor (CIA-1)miR-196b antagomir and COUP-TFII inhibitor ultrasmall lactoferrin-lipid nano-assembliesmiR196b antagomir and COUP-TFII inhibitor ultrasmall lactoferrin-lipid nano-assembliesmiR 196b antagomir and COUP-TFII inhibitor ultrasmall lactoferrin-lipid nano-assemblies
02
Targets
LRP1 (Prolow-density lipoprotein receptor-related protein 1)ITLN1 (Intelectin-1)miR-196b (MicroRNA 196b)
Beyond the preview
Go deeper on miR-196b antagomir + lactoferrin-lipid nano-assemblies.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-196b antagomir + lactoferrin-lipid nano-assemblies.